CORPORATE OVERVIEW

OUR GOAL IS TO BE A LEADER IN THE DEVELOPEMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TRC253, an small molecule inhibitor of wild type and mutated forms of the androgen receptor that is in Phase 2 clinical development for prostate cancer, that is being developed through a collaboration with Janssen Pharmaceutica N.V.; TJ004309, a CD73 antibody that is expected to begin Phase 1 testing in 2019, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma.